{"classes":[{"categories":[{"measurements":[{"comment":"NA=DOR upper limit not reached at time of data cut-off due to insufficient number of responding participants with relapse.","groupId":"OG000","lowerLimit":"5.6","upperLimit":"NA","value":"25.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"For participants who demonstrated a confirmed Complete Response (CR) or partial response (PR), DOR was defined as the time from CR or PR to documented disease progression or death. CR and PR were assessed according to the revised response criteria for malignant lymphoma per Cheson et al. 2007. CR was demonstrated by disappearance of all evidence of disease in the bone marrow, spleen, liver, and lymph nodes. PR was \\>50% decrease in the sum of product diameters (SPD) for ≤6 target masses for lymph nodes and \\>50% decrease in SPD for a single nodule in greatest transverse diameter for spleen and liver, and no size increase in the lymph nodes, spleen, or liver. DOR as assessed by the investigator is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"OG000","title":"Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)"}],"paramType":"MEDIAN","populationDescription":"All participants in Cohort 3 with a baseline efficacy evaluation, at least 1 post-baseline efficacy evaluation, and who demonstrated a PR or CR.","reportingStatus":"POSTED","timeFrame":"Up to approximately 78.5 months","title":"Duration of Response (DOR) in Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)","type":"SECONDARY","unitOfMeasure":"Months"}